SLC5A2 and diabetes mellitus: Furthermore, SGLT-2 inhibitors increase glycosuria and thus enhance diuresis,31 and, combined with preliminary data from the EMPA-REG OUTCOME study,8 it is possible that the clinician anticipated an advantage for SGLT-2 inhibitors in patients with diabetes and congestive heart failure.